Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Fluticasone furoate and vilanterol trifenatate (Breo Ellipta) are used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma in patients aged 5 years and older.
• Reviewed a total of 2 studies from systematic reviews/meta-analyses.
• In adults with asthma, both dual therapy (fluticasone furoate/vilanterol) and triple therapy significantly improved trough FEV1 compared to placebo, showing clinically meaningful improvements. Race was found to be significant in affecting baseline FEV1 but not the trajectory of response over time.
• For COPD, fluticasone furoate/umeclidinium/vilanterol showed significant increases in trough FEV1 more than all other triple comparators except UMEC + FF/VI. It also significantly lowered annualized rates of moderate or severe exacerbations compared to single-inhaler budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR).
• Significant improvements were observed in St. George's Respiratory Questionnaire scores at 24 weeks for COPD patients using fluticasone furoate/umeclidinium/vilanterol versus other therapies, along with reduced rescue medication use compared to BUD/GLY/FOR.
• Breo Ellipta demonstrates substantial efficacy for both asthma and COPD treatments by improving lung function metrics like FEV1, reducing exacerbation rates, enhancing quality-of-life scores such as SGRQ, while subgroup analysis indicates consistent effectiveness across different racial groups despite differences at baseline lung function levels.